Core Viewpoint - Bio Green Med Solution, Inc. (BGMS) has transitioned from the biopharmaceutical industry to focus on fire safety protection and distribution activities, highlighted by significant acquisitions and financial restructuring in 2025 [2][12]. Financial Highlights - As of December 31, 2025, cash and cash equivalents were $3.5 million, a decrease from $3.8 million in 2024 [4]. - Net cash used in operating activities was $4.8 million for 2025, down from $8.0 million in 2024, indicating improved cash management [4]. - Total revenues for the year ended December 31, 2025, were $0.7 million from fire safety product sales, compared to no revenue in 2024 [5][15]. - General and administrative expenses increased to $7.7 million in 2025 from $5.4 million in 2024, primarily due to one-time costs associated with changes in company control [7][15]. - The net loss for the year was $3.0 million, a reduction from $11.2 million in 2024, reflecting improved operational efficiency [11][15]. Business Developments - The acquisition of Fitters Sdn. Bhd. on September 12, 2025, has positioned BGMS to enhance its product offerings in fire safety [2][5]. - The liquidation of the U.K. subsidiary and the sale of the Plogosertib drug have strengthened the company's balance sheet and refocused its business strategy [2][8]. - The company reported a $4.9 million gain on the deconsolidation of its former subsidiary, contributing to total other income of $5.4 million for the year [9][15]. Research and Development - Research and development expenses were significantly reduced to $0.8 million in 2025 from $6.7 million in 2024, as the company ceased expenditures related to its previous drug candidates following the liquidation of its U.K. subsidiary [6][11]. Shareholder Returns - In January 2026, the Board of Directors declared a quarterly cash dividend of $0.15 per share on the company's 6% Convertible Exchangeable Preferred Stock, reflecting a commitment to shareholder returns [8].

Core Viewpoint - Bio Green Med Solution, Inc. has transitioned from the biopharmaceutical industry to focus on fire safety protection and distribution activities, following its acquisition of Fitters Sdn. Bhd. and recent financial updates indicate a shift in operational focus and financial performance [9]. Financial Highlights - As of September 30, 2025, cash and cash equivalents increased to $3.8 million from $3.1 million as of December 31, 2024 [2]. - Net cash used in operating activities was $0.4 million for the three months ended September 30, 2025, with current cash resources expected to fund operations into the first quarter of 2026 [2]. - Product revenue from fire safety equipment sales was $81,000 for the three months ended September 30, 2025, with a cost of sales of $64,000 [3]. Operational Changes - The company completed a one-for-fifteen reverse stock split on July 7, 2025, to meet Nasdaq Capital Market requirements [4]. - In September 2025, the company entered into a Warrant Exchange Agreement to exchange existing warrants for shares of common stock [4]. - The acquisition of Fitters Sdn. Bhd. was finalized on September 12, 2025, making it a wholly-owned subsidiary [4]. - An Asset Purchase Agreement was signed in October 2025 to sell certain assets related to Plogosertib for $300,000, plus potential milestone payments [4]. Research and Development - Research and development expenses were $0 for the three months ended September 30, 2025, a significant decrease from $1.0 million for the same period in 2024, due to the liquidation of the UK subsidiary [5]. - The company paused expenditures related to Plogosertib while exploring alternative formulations [5]. Income and Loss - The net loss for the three months ended September 30, 2025, was $1.0 million, compared to a net loss of $2.0 million for the same period in 2024 [8]. - Total operating expenses decreased from $2.2 million in 2024 to $1.1 million in 2025, primarily due to reduced research and administrative costs [6]. Tax Credits - There were no research and development tax credits for the three months ended September 30, 2025, following the liquidation of the UK subsidiary, which resulted in the loss of eligibility for recoverable tax credits [7]. Shareholder Returns - A quarterly cash dividend of $0.15 per share on the company's 6% Convertible Exchangeable Preferred Stock was declared and paid on November 1, 2025 [4].